Status:

ACTIVE_NOT_RECRUITING

Leber Congenital Amaurosis Inherited Blindness of Gene Therapy Trial(LIGHT)

Lead Sponsor:

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Collaborating Sponsors:

HuidaGene Therapeutics Co., Ltd.

Conditions:

Leber Congenital Amaurosis

Eligibility:

All Genders

8-50 years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of the study is to determine whether HG004 as gene therapy is safe and effective for the treatment of Leber Congenital Amaurosis caused by mutationsin RPE65 gene.

Eligibility Criteria

Inclusion

  • Male or females between 8 and 50 years of age at the time of signing theinformed consent form.
  • Willing to adhere to protocol as evidenced by written informed consent orparental permission and subject assent.
  • Clinical confirmed diagnosis of Leber congenital amaurosis (LCA) andmolecular diagnosis of LCA due to RPE65 mutations.
  • Ability to perform tests of visual and retinal function.
  • Visual acuity of ≤ 20/160 or visual field less than 20 degrees in the eye to beinjected.
  • Acceptable hematology, clinical chemistry, and urine laboratory parameters.

Exclusion

  • OCT examination determined that the outer nuclear layer was not visible inthe planned injection area (Bleb) in the study eye.
  • Presence of epiretinal membrane by OCT.
  • Complicating systemic diseases or clinically significant abnormal baselinelaboratory values.
  • Complicating systemic diseases would include those in which the diseaseitself, or the treatment for the disease, can alter ocular function.
  • Prior ocular surgery within six months.
  • Prior gene therapy or oligonucleotide therapy treatments.
  • Any other condition that would not allow the potential subject to completefollow-up examinations during the study and would, in the opinion of theinvestigator, make the potential subject unsuitable for the study.

Key Trial Info

Start Date :

January 10 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 30 2028

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT06088992

Start Date

January 10 2023

End Date

October 30 2028

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Xinhua Hospital affiliated with Shanghai Jiao Tong UniversitySchool of Medicine

Shanghai, Shanghai Municipality, China